Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2025
Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: A multicentre, randomised, double-blind, placebo-controlled trial
Ann Rheum Dis 2025 Doi: 10.1016/j.ard.2025.10.010. Epub ahead of print
Sun et al. provides the first RCT evidence that low-dose belimumab reduces flares in patients with SLE with low-grade disease activity. Authors evaluated the efficacy of low-dose belimumab for disease flare prevention in Chinese patients with low-grade SLE (SELENA-SLEDAI ≤6).
Keywords:
August 2025
Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: A randomised, double-blind, placebo-controlled, Phase II study
RMD Open 2025;11:e005557 Doi:10.1136/rmdopen-2025-005557
Shen N et al. report that iscalimab was clinically effective and generally well tolerated; in addition, it was devoid of the thromboembolic risk, characteristic of Fc active anti-CD40L therapies.
June 2024
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis
Lupus Sci Med. 2024 May 28;11(1) doi: 10.1136/lupus-2024-001156
The combination of anti-dsDNA and anti-SSA/Ro60 serotype may help to foretell the patient’s renal response to belimumab. Investigators here aimed to explore the effectiveness of belimumab on active LN, exploring predictors, including serological biomarkers, of renal response to belimumab in a real-world setting.